Table 1.
No. | Name | SGLT2 IC50 (nmol/L) | SGLT1 IC50 (nmol/L) | Selectivity (fold) | Bioavailability (%) | Condition |
---|---|---|---|---|---|---|
55 | Canagliflozin | 2.2 | 910 | 414 | 78 | Launched in 2013 |
56 | Dapagliflozin | 1.1 | 1390 | 1263 | 78 | Launched in 2014 |
57 | Empagliflozin | 3.1 | > 930 | >300 | >90 | Launched in 2014 |
58 | Ipragliflozin | 7.4 | 1880 | 254 | 71.7 | Launched in 2014 |
59 | Tofogliflozin | 2.9 | 8444 | 2912 | 85 | Phase III |